Nonadherence to cervical cancer screening guidelines in commercially insured US adults
Peer-Reviewed Publication
Updates every hour. Last Updated: 11-Dec-2025 04:11 ET (11-Dec-2025 09:11 GMT/UTC)
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, HER2-negative breast cancer, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.
For the first time, real-time imaging tracks what happens to cancer cells arriving in the brain, identifying a new strategy to prevent brain tumors. Published in Cancer Research, a journal of the American Association for Cancer Research, the study identifies two proteins that seed cells use to avoid being destroyed by microglia when they first arrive. By genetically removing these proteins, researchers showed that microglia play a key role in eliminating cancer cells during the early stage of their arrival in the brain.
Scientists at Northwestern University have developed the fastest test yet for diagnosing hepatitis C virus (HCV). The highly accurate diagnostic delivers results to patients in just 15 minutes — up to 75% faster than other rapid HCV tests. This speed is crucial for kickstarting patients’ treatment before they leave their appointment, potentially preventing painful, expensive complications and even death.
The research behind the new test will be published Dec. 10 in The Journal of Infectious Diseases.
HCV can lead to a chronic hepatitis C infection, which affects an estimated 50 million people globally and causes approximately 242,000 deaths annually, largely due to resulting cirrhosis and liver cancer. While the infection is curable with an 8- to 12-week course of medication, treatment rates remain low partially due to lack of affordable and easily accessible diagnostic tests.
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.